Patents Assigned to NEURONASAL, INC.
  • Methods of administering glutathione precursors
    Patent number: 12648920
    Abstract: The present disclosure describes methods of administering a pharmaceutical composition comprising a glutathione precursor and a thermoresponsive polymer via intranasal administration. In some embodiments, intranasal administration of the glutathione precursor can be used to treat a condition, for example, a central nervous system disorder.
    Type: Grant
    Filed: February 21, 2023
    Date of Patent: June 9, 2026
    Assignee: Neuronasal, Inc.
    Inventors: Douglas A. Greene, Thomas I. Bradshaw
  • Intranasal administration of n-acetylcysteine and uses thereof
    Patent number: 12594254
    Abstract: The present disclosure describes methods comprising administering N-acetylcysteine (NAC) or a pharmaceutically-acceptable salt or congener thereof. The disclosed methods can be used to treat a brain disorder.
    Type: Grant
    Filed: February 7, 2023
    Date of Patent: April 7, 2026
    Assignee: Neuronasal, Inc.
    Inventors: Douglas A. Greene, Thomas I. Bradshaw
  • Methods of treating brain disorders
    Patent number: 12414929
    Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: September 16, 2025
    Assignees: Neuronasal, Inc., Burke Neurological Institute
    Inventors: Douglas A. Greene, Rajiv R. Ratan, Thomas I. Bradshaw
  • Methods of treating brain disorders
    Patent number: 12090130
    Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: September 17, 2024
    Assignees: Neuronasal, Inc., Burke Neurological Institute
    Inventors: Douglas A. Greene, Rajiv R. Ratan, Thomas I. Bradshaw
  • Use of N-acetylcysteine to treat central nervous system disorders
    Patent number: 11963939
    Abstract: The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E2.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: April 23, 2024
    Assignees: Neuronasal, Inc., Burke Neurological Institute
    Inventors: Rajiv R. Ratan, Saravanan Karuppagounder, Thomas I. Bradshaw
  • Use of N-acetylcysteine to treat central nervous system disorders
    Patent number: 11660278
    Abstract: The present disclosure describes methods of treating a central nervous system condition associated with oxidative stress using a 5-lipoxigenase activating protein (FLAP) inhibitor, for example, N-acetylcysteine or nordihydroguaiaretic acid. The present disclosure also describes methods of treating a central nervous system condition with N-acetylcysteine and a second therapeutic agent such as prostaglandin E2.
    Type: Grant
    Filed: December 2, 2019
    Date of Patent: May 30, 2023
    Assignees: NEURONASAL, INC., BURKE NEUROLOGICAL INSTITUTE
    Inventors: Rajiv R. Ratan, Saravanan Karuppagounder, Thomas I. Bradshaw